Biomx Incis A Clinical Stage Biotechnology Company That Develops Phage Based Therapies Targeting Pathogenic Bacteria Linked To Chronic Diseases And Skin Conditionsthe Company Specializes In Creating Natural And Engineered Bacteriophage Cocktails That Effectively Target Harmful Bacteria While Preserving Beneficial Microbiotaits Therapeutic Focus Includes Conditions Such As Cystic Fibrosisinflammatory Bowel Diseaseatopic Dermatitisprimary Sclerosing Cholangitisand Colorectal Cancer Biomx Employs Proprietary Platformsincluding Boltwhich Integrates Computational Biology And Synthetic Engineering To Optimize Phage Selection And Designthe Company Collaborates With Leading Institutions Like The Weizmann Institute Of Science And Mit To Enhance Its Research Capabilitieswith A Focus On Personalized Treatments And Broad Spectrum Cocktailsbiomx Aims To Advance Its Clinical Pipelineaddressing High Unmet Need Conditions In The Healthcare And Biotechnology Sectors
United States
